| Biomarker ID | 1481 |
| PMID | 25075250 |
| Year | 2014 |
| Biomarker | miR-21 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in GS ≥ 8 (Benign: 0.636 ± 0.048; malignant: 0.521 ± 0.027) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: MicroRNAs in cancer; cellular protein modification process; protein modification process; protein binding; negative regulation of cellular metabolic process |
| Experiment | Gleason Score ≥ 8 Vs Gleason Score < 8 |
| Type of Biomarker | Prognostic |
| Cohort | 215 samples were chosen for analysis. 204 were malignant and 11 were benign. 147 with GS ≥ 8 and 57 with GS <8 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.004 |
| Method Used | In Situ hybridization (ISH) |
| Clinical | No |
| Remarks | Results for epithelial carcinoma cell study |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |